NUVB
$4.22-0.04 (-0.94%)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung canc...
Recent News
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings
If you are wondering whether Nuvation Bio's share price lines up with its underlying value, the recent action in the stock gives you plenty to think about. The shares last closed at US$4.22, with returns of 123.3% over 1 year and 157.3% over 3 years, but also a 26.9% decline over 30 days and a 50.8% decline year to date. These swings have put valuation in the spotlight, as investors weigh up what the current price says about expectations for Nuvation Bio. Recent coverage has focused on how...
Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress
Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 most active penny stocks to buy. As of March 16, 2026, Wall Street remains optimistic about Nuvation Bio Inc. (NYSE:NUVB). With over 90% of analysts covering Nuvation Bio Inc. (NYSE:NUVB) maintaining bullish ratings, the consensus price target is $12.00, indicating a potential upside of 166.67%. As […]
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here’s Why
Nuvation Bio Inc. (NYSE:NUVB) is one of the best penny stocks to buy according to Reddit. On March 3, RBC Capital cut the price target on Nuvation Bio Inc. (NYSE:NUVB) to $13 from $12 while maintaining an Outperform rating on the shares. The rating update came after the company reported its fiscal Q4 results, with […]
Nuvation Bio Inc. Q4 2025 Earnings Call Summary
Moby summary of Nuvation Bio Inc.'s Q4 2025 earnings call
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch
Nuvation Bio Inc. (NYSE:NUVB) is one of the best low cost stocks to buy under $5. On March 2, Nuvation Bio (NUVB) reported a pivotal 2025 marked by the FDA approval and rapid commercial launch of Ibtrozi (Taletrectinib) for ROS1-positive non-small cell lung cancer. With 432 new patient starts by year-end, the drug’s uptake outpaced […]